Organization
Institut de Recherches Internationales Servier, Suresnes, France
2 abstracts
Abstract
ASSESSMENT OF S95011 (OSE-127, LUSVERTIKIMAB), AN ANTI-INTERLEUKIN 7 RECEPTOR MONOCLONAL ANTIBODY, IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: AN INTERNATIONAL MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2A STUDYOrg: RheumatologySA, Adelaide, Australia, Vita Verum Medical Private Practice, Skékesfehervar, Hungary, Institut de Recherches Internationales Servier, Suresnes, France,
Abstract
BASELINE CHARACTERISTICS OF THE STUDY POPULATION IN ROCCELLA, A PHASE 2 CLINICAL TRIAL EVALUATING THE EFFICACY AND THE SAFETY OF S201086/GLPG1972 IN PATIENTS WITH KNEE OSTEOARTHRITISOrg: Institut de Recherches Internationales Servier, Suresnes, France, Galapagos, Mechelen, Belgium, Institute of Anatomy & Cell Biology, Paracelsus Medical University, Salzburg, Austria, Chondrometrics GmbH, Ainring, Germany,